<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName A++V2.4.dtd?>
<?SourceDTD.Version 2.4?>
<?ConverterInfo.XSLTName springer2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id>
    <journal-id journal-id-type="iso-abbrev">BMC Cancer</journal-id>
    <journal-title-group>
      <journal-title>BMC Cancer</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1471-2407</issn>
    <publisher>
      <publisher-name>BioMed Central</publisher-name>
      <publisher-loc>London</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10239192</article-id>
    <article-id pub-id-type="publisher-id">10970</article-id>
    <article-id pub-id-type="doi">10.1186/s12885-023-10970-8</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Database</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>ABPEPserver: a web application for documentation and analysis of substitutants</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" corresp="yes" equal-contrib="yes">
        <name>
          <surname>Pataskar</surname>
          <given-names>Abhijeet</given-names>
        </name>
        <address>
          <email>a.pataskar@nki.nl</email>
        </address>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author" equal-contrib="yes">
        <name>
          <surname>Montenegro Navarro</surname>
          <given-names>Jasmine</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2848-2473</contrib-id>
        <name>
          <surname>Agami</surname>
          <given-names>Reuven</given-names>
        </name>
        <address>
          <email>r.agami@nki.nl</email>
        </address>
        <xref ref-type="aff" rid="Aff1">1</xref>
        <xref ref-type="aff" rid="Aff2">2</xref>
      </contrib>
      <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.430814.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 0674 1393</institution-id><institution>Division of Oncogenomics, </institution><institution>Oncode Institute, The Netherlands Cancer Institute, </institution></institution-wrap>Plesmanlaan 121, 1066CX Amsterdam, the Netherlands </aff>
      <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.5645.2</institution-id><institution-id institution-id-type="ISNI">000000040459992X</institution-id><institution>Erasmus MC, Department of Genetics, </institution><institution>Rotterdam University, </institution></institution-wrap>Rotterdam, the Netherlands </aff>
    </contrib-group>
    <pub-date pub-type="epub">
      <day>3</day>
      <month>6</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>3</day>
      <month>6</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2023</year>
    </pub-date>
    <volume>23</volume>
    <elocation-id>502</elocation-id>
    <history>
      <date date-type="received">
        <day>4</day>
        <month>5</month>
        <year>2022</year>
      </date>
      <date date-type="accepted">
        <day>16</day>
        <month>5</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2023</copyright-statement>
      <license>
        <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p>
      </license>
    </permissions>
    <abstract id="Abs1">
      <sec>
        <title>Background</title>
        <p id="Par1">Cancer immunotherapy is implemented by identifying antigens that are presented on the cell surface of cancer cells and illicit T-cell response (Schumacher and Schreiber, Science 348:69–74, 2015; Waldman et al., Nat Rev Immunol 20:651–668, 2020; Zhang et al., Front Immunol 12:672,356, 2021b). Classical candidates of such antigens are the peptides resulting from genetic alterations and are named “neoantigen" (Schumacher and Schreiber, Science 348:69–74, 2015). Neoantigens have been widely catalogued across several human cancer types (Tan et al., Database (Oxford) 2020;2020b; Vigneron et al., Cancer Immun 13:15, 2013; Yi et al., iScience 24:103,107, 2021; Zhang et al., BMC Bioinformatics 22:40, 2021a). Recently, a new class of inducible antigens has been identified, namely Substitutants, that are produced as a result of aberrant protein translation (Pataskar et al., Nature 603:721–727, 2022).</p>
      </sec>
      <sec>
        <title>Main</title>
        <p id="Par2">Catalogues of Substitutant expression across human cancer types, their specificity and association to gene expression signatures remain elusive for the scientific community's access. As a solution, we present ABPEPserver, an online database and analytical platform that can visualize a large-scale tumour proteomics analysis of Substitutant expression across eight tumour types sourced from the CPTAC database (Edwards et al., J Proteome Res 14:2707–2713, 2015). Functionally, ABPEPserver offers the analysis of gene-association signatures of Substitutant peptides, a comparison of enrichment between tumour and tumour-adjacent normal tissues, and a list of peptides that serve as candidates for immunotherapy design. ABPEPserver will significantly enhance the exploration of aberrant protein production in human cancer, as exemplified in a case study.</p>
      </sec>
      <sec>
        <title>Conclusion</title>
        <p id="Par3">ABPEPserver is designed on an R SHINY platform to catalogue Substitutant peptides in human cancer. The application is available at <ext-link ext-link-type="uri" xlink:href="https://rhpc.nki.nl/sites/shiny/ABPEP/">https://rhpc.nki.nl/sites/shiny/ABPEP/</ext-link>. The code is available under GNU General public license from GitHub (<ext-link ext-link-type="uri" xlink:href="https://github.com/jasminesmn/ABPEPserver">https://github.com/jasminesmn/ABPEPserver</ext-link>).</p>
      </sec>
      <sec>
        <title>Supplementary Information</title>
        <p>The online version contains supplementary material available at 10.1186/s12885-023-10970-8.</p>
      </sec>
    </abstract>
    <kwd-group xml:lang="en">
      <title>Keywords</title>
      <kwd>Substitutants</kwd>
      <kwd>Codon reassignment</kwd>
      <kwd>Translation</kwd>
      <kwd>Cancer</kwd>
      <kwd>Immunotherapy</kwd>
    </kwd-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004622</institution-id>
            <institution>KWF Kankerbestrijding</institution>
          </institution-wrap>
        </funding-source>
        <award-id>13647</award-id>
        <principal-award-recipient>
          <name>
            <surname>Agami</surname>
            <given-names>Reuven</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100011199</institution-id>
            <institution>FP7 Ideas: European Research Council</institution>
          </institution-wrap>
        </funding-source>
        <award-id>832844</award-id>
        <principal-award-recipient>
          <name>
            <surname>Agami</surname>
            <given-names>Reuven</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
    </funding-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>issue-copyright-statement</meta-name>
        <meta-value>© BioMed Central Ltd., part of Springer Nature 2023</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="Sec1">
    <title>Background</title>
    <p id="Par4">Cancer immunotherapy has improved cancer patients' treatment possibilities, especially those with metastatic spread [<xref ref-type="bibr" rid="CR19">19</xref>]. Although the success, the clinical outcome of immunotherapy is not consistent both within and across cancer entities. A sufficient infiltration into the tumour microenvironment and activation of effector T-cells against cancer cells can be seen as predictors for responses to T-cell-based immunotherapies [<xref ref-type="bibr" rid="CR15">15</xref>–<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR21">21</xref>–<xref ref-type="bibr" rid="CR23">23</xref>]. However, cancer cells have developed multiple mechanisms to inhibit anticancer immunity's activity, effecting antigen presentation on Human Leukocyte Antigen (HLA) class I receptor molecules [<xref ref-type="bibr" rid="CR10">10</xref>].</p>
    <p id="Par5">Based on the responsiveness to immunotherapy, a tumour type could be classified as “hot”, i.e. responsive and “cold”, i.e. non-responsive tumours [<xref ref-type="bibr" rid="CR2">2</xref>]. A critical delineator between these tumour-types is the identification of presentable antigens that harbour the ability to elicit T-cell responses [<xref ref-type="bibr" rid="CR4">4</xref>]. Recently, a new class of antigens were identified, namely Substitutants, which are produced as a result of aberrant translation consequential of T cell infiltration associated endogenous tryptophan depletion [<xref ref-type="bibr" rid="CR13">13</xref>] (Fig. <xref rid="Fig1" ref-type="fig">1</xref>A). Substitutants are defined as peptides arising because of Tryptophan to Phenylalanine substitution in cancer cells as a result of tryptophan shortage. Importantly, Substitutant peptides harbour immunotherapeutic potential owing to their ability to elicit T cell responses [<xref ref-type="bibr" rid="CR13">13</xref>] (Fig. <xref rid="Fig1" ref-type="fig">1</xref>B). Hence, it is not only necessary to correctly identify and catalogue presentable substitutants across multiple human tumour-types, but it is also essential that we understand molecular pathways that enrich their production and presentation.<fig id="Fig1"><label>Fig. 1</label><caption><p>Substitutants as novel cancer antigens. <bold>A</bold> A flowchart depicting the pathways in cancer cells leading to the generation of W &gt; F substitutants. <bold>B</bold> A model describing the mechanisms leading to the presentation of substitutant antigens and consequential T cell killing of cancer cells</p></caption><graphic xlink:href="12885_2023_10970_Fig1_HTML" id="MO1"/></fig></p>
    <p id="Par6">To identify and characterize such substitutant peptides, we undertook a large-scale proteomic analysis of multiple cancer types sourced from the CPTAC consortium [<xref ref-type="bibr" rid="CR8">8</xref>]. To make this analysis more accessible to the scientific community, we developed an online database called ABPEPserver, which harbours substitutant information from eight independent human tumour types, namely Lung Squamous Cell Carcinoma (LSCC, [<xref ref-type="bibr" rid="CR14">14</xref>]), Clear Cell Renal Cell Carcinoma (CCRCC, [<xref ref-type="bibr" rid="CR5">5</xref>]), Glioblastoma (GBM, [<xref ref-type="bibr" rid="CR20">20</xref>]), Head and Neck Squamous Cell Carcinoma (HNSCC, [<xref ref-type="bibr" rid="CR11">11</xref>]), Hepatocellular Carcinoma (HCC, [<xref ref-type="bibr" rid="CR9">9</xref>]), Ovarian Sereous Cystadenocarcinoma (OVSCC, [<xref ref-type="bibr" rid="CR12">12</xref>]), Pancreatic Ductal Carcinoma (PDA, [<xref ref-type="bibr" rid="CR3">3</xref>]), Uterine Corpus Endometrial Carcinoma (UCEC, [<xref ref-type="bibr" rid="CR7">7</xref>]). ABPEPserver provides background information on the substitutant peptides and their analyzed cancer type description, a comparative analysis of substitutant expression in tumours and tumour-adjacent normal tissues, and downloadable links of text files harbouring this information. These substitutant peptides can then be used for predicting neoepitopes for potential immunotherapy tests. Altogether, ABPEPserver is an ease-of-access web tool useful towards designing immunotherapeutic substitutant candidates (Fig. <xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Design of ABPEPserver. A model describes the ABPEPserver. The server offers a web interface for easy data accessibility, analytical tools for biological interpretation, and the possibility of downloading relevant data in text format. The database was designed in MySQL, uses W-peptide counts, Gene expression profiles downloaded from the PDC commons Databases, identified substitutant peptides and Gene cluster data information for eight cancer types, sourcing data from 911 tumours and 558 tumour-adjacent normal tissue</p></caption><graphic xlink:href="12885_2023_10970_Fig2_HTML" id="MO2"/></fig></p>
  </sec>
  <sec id="Sec2">
    <title>Construction and content</title>
    <sec id="Sec3">
      <title>Proteomic analysis of substitutant peptide expression</title>
      <p id="Par7">As previously published, a reanalysis of substituants peptide expression was undertaken [<xref ref-type="bibr" rid="CR13">13</xref>]. Briefly, Philosopher pipeline was used to detect endogenous substituants in the large-scale proteomics dataset with the same parameters as previously published [<xref ref-type="bibr" rid="CR6">6</xref>].</p>
      <p id="Par8">Mass spectrometry-derived processed spectra (mzML) files for all independent cancer types were obtained from the CPTAC database [<xref ref-type="bibr" rid="CR8">8</xref>]. The database of protein sequences was prepared in one of two ways. First, the human proteome with all instances of tryptophan amino acids in the proteome changed to all other amino acids except Arginine and Lysine was used as a database in the scan – referred to as database 1(fully substitutant). Second, to optimize true positives, we generated a second database (optimized database) which includes the canonical human proteome (UniPROT) with the substitutant tryptic peptides (length &gt; 5 &amp; &lt; 50 amino acids) spanning tryptophan residue and tryptophan substituted to all other amino acids. The analysis of both these databases is presented separately on the server. Additional details on the FASTA file are available on the GITHUB page and the description section on the server. Briefly, MSFragger searches the mzML spectral files against the custom database for peptide detection with the following parameters; Precursor mass lower: − 20 ppm, Precursor mass upper: 20 ppm, precursor mass tolerance: 20 ppm, calibrate mass: True, Deisotoping: True, mass offset: False, isotope error: Standard, digestion: Strictly tryptic (Max. missed cleavage: 2), Variable modifications: 15.99490 M 3, 42.01060 [^ 1, 144.1021 n^ 1, 144.1021 S 1, Min Length: 7, Max Length: 50, digest mass range: 500:5000 Daltons, Max Charge: 2, remove precursor range: − 1.5, 1.5, topN peaks: 300, minimum peaks: 15, precursor range: 1:6, add Cysteine: 57.021464, add Lysine: 229.162932, among other basic parameters (Supplementary Table <xref rid="MOESM2" ref-type="media">1</xref>). Next, PeptideProphet validates detected peptides with the following parameters; accmass: TRUE, decoyprobs: TRUE, expectScore: TRUE, Glycosylation: FALSE, ICAT: FALSE, masswidth: 5, minimum probability after first pass of a peptide: 0.9, minimum number of NTT in a peptide: 2, among other parameters (Supplementary Table <xref rid="MOESM2" ref-type="media">1</xref>). Isobaric quantification was then undertaken the following parameters (bestPSM: TRUE, level: 2, minProb 0.7, ion purity cut-off: 0.5, tolerance: 20 ppm, among other parameters (Supplementary Table <xref rid="MOESM2" ref-type="media">1</xref>). Next, to only retain confident peptides, peptides were filtered using stringent False Discovery Rate (FDR) filtering. The following parameters were used for FDR filtering; FDR &lt; 0.01, peptideProbability: 0.7, among other parameters (Supplementary Table <xref rid="MOESM2" ref-type="media">1</xref>). Next, TMT-integrator was used to create integrated reports with isobaric quantification across all samples with the following parameters (retention time normalization: False, minimum peptide probability on top of FDR filtering: 0.9, among other parameters (Supplementary Table <xref rid="MOESM2" ref-type="media">1</xref>).</p>
      <p id="Par9">Substitutant peptides were fetched from the reports of TMT Integrator (version 3.1.0). Using a R-script, peptides with a log2-transformed intensity score above 0 in a sample were observed as positively detected peptides in that sample. As described before [<xref ref-type="bibr" rid="CR13">13</xref>], for intra-tumour type analysis a filter for the maximum number of samples was applied to retain peptides with higher specificity in expression, except for W &gt; F substitutants due to their exclusive significant and specific distribution wherever significant. All tumour types have been demonstrated to be exclusive with the analysis of database 1 [<xref ref-type="bibr" rid="CR13">13</xref>], while GBM, UCEC, and PDA did not show this exclusivity in the analysis of database 2. This optimizes the signal for gene expression correlation analysis. Furthermore, this script was used to plot bar plots depicting the cumulative number of tryptophan substitutants detected in the scans.</p>
      <p id="Par10">Gene expression data was downloaded in GCT format from PDC database. The counts of W-substitutants were combined for each sample with gene expression profiles. PERL scripts were designed to count the number of substitutants when a gene is lowly expressed (intensity &lt; 0) or highly expressed (intensity &gt; 0). <italic>P</italic>-values for comparison are calculated using Wilcoxen t-test.</p>
    </sec>
    <sec id="Sec4">
      <title>Data sources</title>
      <p id="Par11">Eight independent human tumour-types, namely Lung Squamous Cell Carcinoma (LSCC, [<xref ref-type="bibr" rid="CR14">14</xref>]), Clear Cell Renal Cell Carcinoma (CCRCC, [<xref ref-type="bibr" rid="CR5">5</xref>]), Glioblastoma (GBM, [<xref ref-type="bibr" rid="CR20">20</xref>]), Head and Neck Squamous Cell Carcinoma (HNSCC, [<xref ref-type="bibr" rid="CR11">11</xref>]), Hepatocellular Carcinoma (HCC, [<xref ref-type="bibr" rid="CR9">9</xref>]), Ovarian Serous Cystadenocarcinoma (OVSCC, [<xref ref-type="bibr" rid="CR12">12</xref>]), Pancreatic Ductal Carcinoma (PDA, [<xref ref-type="bibr" rid="CR3">3</xref>]), Uterine Corpus Endometrial Carcinoma (UCEC, [<xref ref-type="bibr" rid="CR7">7</xref>]), were analysed to generate ABPEPserver database (Table <xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR1">1</xref>]. CPTAC IDS of the datasets are provided in Table<xref rid="Tab1" ref-type="table">1</xref> and Supplementary Table <xref rid="MOESM3" ref-type="media">2</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>This table details the tumour types used to build ABPEPserver, with the information on identified substitutants and the number of tumours and adjacent normal tissues used to build the analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Cancer type</th><th align="left">PDC study ID</th><th align="left">Substitutants</th><th align="left"># Tumor<break/>samples</th><th align="left"># Normal samples</th></tr></thead><tbody><tr><td align="left">Clear Cell Renal Carcinoma</td><td align="left">PDC000127</td><td align="left">3623</td><td align="left">110</td><td align="left">84</td></tr><tr><td align="left">Glioblastoma</td><td align="left">PDC000204</td><td align="left">3978</td><td align="left">100</td><td align="left">10</td></tr><tr><td align="left">Head and neck Squamous Cell Carcinoma</td><td align="left">PDC000221</td><td align="left">3212</td><td align="left">105</td><td align="left">53</td></tr><tr><td align="left">Hepatocellular Carcinoma</td><td align="left">PDC000198</td><td align="left">9787</td><td align="left">165</td><td align="left">165</td></tr><tr><td align="left">Lung Squamous Cell Carcinoma</td><td align="left">PDC000234</td><td align="left">8237</td><td align="left">110</td><td align="left">101</td></tr><tr><td align="left">Ovarian Serous Cystadenocarcinoma</td><td align="left">PDC000110</td><td align="left">892</td><td align="left">84</td><td align="left">22</td></tr><tr><td align="left">Pancreatic Ductal Adenocarcinoma</td><td align="left">PDC000270</td><td align="left">3440</td><td align="left">137</td><td align="left">74</td></tr><tr><td align="left">Uterine Corpus Endometrial Carcinoma</td><td align="left">PDC000125</td><td align="left">4329</td><td align="left">100</td><td align="left">49</td></tr></tbody></table></table-wrap></p>
    </sec>
    <sec id="Sec5">
      <title>Design of database and web tools</title>
      <p id="Par12">A MySQL database was created to efficiently organize output data and avoid storage difficulties of multiple large files. With a database, data is efficiently stored and easily retrievable. For each cancer type, we stored substitutant counts. We identified individual substitutant peptides and gene cluster data from the proteomic analysis and associated gene expression. Data for tumour and adjacent normal tissue samples are made distinguishable for comparison.</p>
    </sec>
    <sec id="Sec6">
      <title>Implementation</title>
      <p id="Par13">ABPEPserver is a R/Shiny application which allows users to interact with and visualize our data and analysis. We implemented the R package RMySQL 0.10.23 to connect our database to the application.</p>
      <p id="Par14">Users are provided with background scientific information, methods and cancer types used in the study on the home page of the ABPEPserver. Users are provided then two options for using the web tools, viz. Analyze and tryptophan to phenylalanine (W &gt; F) Substitutants. In the “Analyze” module, the user can explore the enrichment of substitutants and their association with molecular gene expression signatures. On the other hand, the “W &gt; F Substitutants” module can be employed to browse individual substitutants in multiple cancer types and tumour vs adjacent normal tissue expression. Here, the information on the database used to detect the peptide is also added. The corresponding files of this module are downloadable.</p>
    </sec>
  </sec>
  <sec id="Sec7">
    <title>Utility and discussion</title>
    <sec id="Sec8">
      <title>Description of utility</title>
      <p id="Par15">ABPEPserver is a web database that serves as a platform to identify and characterize the expression of substitutants, a recently identified class of aberrant proteins with immunotherapeutic potential, across various human cancer types. In addition, ABPEPserver allows the analysis of the association of molecular gene expression signatures to the enrichment of substituants. As an example, such analysis was demonstrated to be essential for pinpointing the role of T-cell infiltration and direct causal proteins (such as IDO1) in the expression of W &gt; F substitutant peptides (Fig. <xref rid="Fig2" ref-type="fig">2</xref>) [<xref ref-type="bibr" rid="CR13">13</xref>]. This shows that the expression of substitutant peptides is regulated by IDO1 expression, which is induced via the T-cell infiltration pathway.</p>
      <p id="Par16">Furthermore, ABPEPserver displays enrichment differences of substitutant peptides in tumours and tumour-adjacent normal tissues, an analysis that can be utilized for underpinning cancer-specific underlying mechanisms. Lastly, downloadable text files from the ABPEPserver can be used to identify common cancer-specific substitutants that can provide the foundation for predicting neoepitopes for a wide-ranging immunotherapeutic application. Altogether, ABPEPserver provides detailed information on the identity of the substitutants, their cancer-specific expression and immunotherapeutic potential.</p>
    </sec>
    <sec id="Sec9">
      <title>User interface</title>
      <sec id="Sec10">
        <title>Main page</title>
        <p id="Par17">The main page of ABPEPserver displays relevant information, methods in detail and cancer types used in the analysis in the construction of ABPEPserver along with supplementary information on each cancer type (Supplementary Fig. <xref rid="MOESM1" ref-type="media">1</xref>A).</p>
      </sec>
      <sec id="Sec11">
        <title>Analyze module</title>
        <p id="Par18">The “Analyze” module allows the user to select the cancer type and database of interest and plot Barplots, scatter-contour plots and Violin plots for analytical purposes (Supplementary Fig. <xref rid="MOESM1" ref-type="media">1</xref>B). Barplots allow the display of various types of W-substitutants and their relative enrichment concerning each other. Scatter contour plots allow the association analysis of all proteins to the number of substitutants. Violin plots allow the analysis of individual protein association with the number of substitutants. For example, IDO1 expression was associated with substitutant peptide expression using this analysis (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). IDO1 is an enzyme that catabolizes Tryptophan molecules in the cell; hence, the association of IDO1 expression with substitutants is biologically meaningful. Hence, Analyze module provide critical biological insights into the substitutant peptide expression and can be used by the users to design cancer-specific immunotherapy study.</p>
      </sec>
      <sec id="Sec12">
        <title>W &gt; F substitutants module</title>
        <p id="Par19">This module allows users to select the cancer type and database of interest and plot and download individual peptides for potential immunotherapeutic applications (Supplementary Fig. <xref rid="MOESM1" ref-type="media">1</xref>C). The utility of this module is demonstrated in a case study below.</p>
      </sec>
    </sec>
    <sec id="Sec13">
      <title>Case study: identification of immunocompetent substitutants using ABPEPserver</title>
      <p id="Par20">Using the “W &gt; F Substitutants” module for UCEC (Uterine Cancer) and the displayed scatter-plot, two example peptides ( fGHPAGK and SVLGCfK) were identified using fully substitutant database (database 1) and found to be expressed in a highly tumour-specific manner (73 tumours and 0 tumour-adjacent normal tissue, 45 tumours and 0 tumour-adjacent normal tissue respectively) (Fig. <xref rid="Fig3" ref-type="fig">3</xref>A). This tumour-specific expression implies that it is feasible to target these antigens specifically in cancerous tissues without harbouring any reactivity against normal cells if these peptides can present on the cell surface and bind to HLA molecules. Indeed, NETMHC [<xref ref-type="bibr" rid="CR1">1</xref>] based prediction shows that many combinations of these two peptides have potentially strong binding affinity to one or multiple HLA super-alleles (Fig. <xref rid="Fig3" ref-type="fig">3</xref>B-C). This analysis indicates that the discovered peptides potentially harbour strong immunotherapeutic potential and warrant experimental validation. Thus, ABPEPserver can be used to identify potential cancer-specific antigens for immunotherapeutic applications.<fig id="Fig3"><label>Fig. 3</label><caption><p>Case-study: Utility of ABPEPserver. <bold>A</bold> A scatter plot from ABPEPserver (W &gt; F Substitutants module) for UCEC (Uterine Cancer), depicting total occurrences in tumour tissue samples on X-axis and Total occurrences in adj. normal tissue samples on Y-axis. Identification of two peptides that are selected to be highly tumour-specifically expressed. The database used for this scatter plot is the fully substitutant database (database 1). <bold>B</bold>, <bold>C</bold> Tables displaying peptide combinations for the selected peptides in (A) that have HLA-binding ability to one or more HLA super alleles. Rank is displayed as inverse rank from NETMHC <sup>23</sup>analysis where peptides rank &lt; 1 are identified as strong binders and rank &gt; 1 &amp; rank &lt; 2 are identified as weak binders</p></caption><graphic xlink:href="12885_2023_10970_Fig3_HTML" id="MO3"/></fig></p>
    </sec>
    <sec id="Sec14">
      <title>Future outlook</title>
      <p id="Par21">In future, we plan to expand ABPEPserver functionality towards harbouring other kinds of aberrant peptides that are discovered, such as ribosomal-frameshift-associated chimeric peptides. In response to tryptophan shortage, it has been observed that ribosomes change the frame at the tryptophan-associated “TGG” codon, leading to the synthesis of W-chimera. Since W-chimera were only observed in cell-culture systems, it is important to analyze whether W-chimeras is also expressed in the eight cancer types analyzed here. If the expression is observed, the next pursuit is the association of gene expression pathways.</p>
    </sec>
  </sec>
  <sec id="Sec15">
    <title>Conclusions</title>
    <p id="Par22">We present ABPEPserver, a database of aberrant Substitutant peptides in human cancer. Substitutant peptides result from tryptophan to phenylalanine misincorporation events and are generated in human cancer due to T-cell infiltration and subsequent tryptophan depletion [<xref ref-type="bibr" rid="CR13">13</xref>]. The “Analyze” module of ABPEPserver allows exploration of gene expression signature of substitutant peptide expression in multiple human cancer types, organized as peptides detected in tumours and tumour-adjacent normal tissue. The W &gt; F “Substitutant” modules allow exploration of individual Substitutant peptides in multiple patient samples and have download features. The presented case study exemplifies that the substitutant peptides identified by ABPEPserver harbour immunotherapeutic potential. Hence, ABPEPserver is a valuable resource to the scientific community invested in anti-tumour immunotherapy development.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Information</title>
    <sec id="Sec16">
      <p>
        <supplementary-material content-type="local-data" id="MOESM1">
          <media xlink:href="12885_2023_10970_MOESM1_ESM.pdf">
            <caption>
              <p><bold>Additional file 1: Supplementary Figure 1.</bold> Description: ABPEPserver design and modules. (A) Introduction Main page of ABPEPserver provides background information, methods and Cancer-types used for the development of the server. (B) User entry page of “Analyze module” wherein user can select cancer-type of interest and one of the three Analyze sub-modules (C) User entry page “W&gt;F Substitutant” peptides with browse function.</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="MOESM2">
          <media xlink:href="12885_2023_10970_MOESM2_ESM.xlsx">
            <caption>
              <p><bold>Additional file 2: Supplementary Table 1.</bold> Philosopher parameters used for scanning and detecting substitutant peptides in cancer proteomes.</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="MOESM3">
          <media xlink:href="12885_2023_10970_MOESM3_ESM.xlsx">
            <caption>
              <p><bold>Additional file 3: Supplementary Table 2.</bold> The table detailing publications associated to the analyzed data.</p>
            </caption>
          </media>
        </supplementary-material>
      </p>
    </sec>
  </sec>
</body>
<back>
  <fn-group>
    <fn>
      <p>
        <bold>Publisher’s Note</bold>
      </p>
      <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
    </fn>
    <fn>
      <p>Abhijeet Pataskar and Jasmine Montenegro Navarro contributed equally.</p>
    </fn>
  </fn-group>
  <ack>
    <title>Acknowledgements</title>
    <p>The authors would like to thank members of the Agami Group for their feedback. The authors would also like to thank Bhagyashree Joshi for help with the figures created with BioRender.com.</p>
  </ack>
  <notes notes-type="author-contribution">
    <title>Authors’ contributions</title>
    <p>AP designed the study and bioinformatics analysis. JMN helped with bioinformatics analysis and designed the server. RA designed and supervised the study. The author(s) read and approved the final manuscript.</p>
  </notes>
  <notes notes-type="funding-information">
    <title>Funding</title>
    <p>R.A. is supported by the Dutch cancer society (KWF projects 11037 and 13647), the European research council (ERC-2018-ADG—GA 832844), NWO computational grant (2021.034) and the AvL Foundation.</p>
  </notes>
  <notes notes-type="data-availability">
    <title>Availability of data and materials</title>
    <p>The application, data, and material are freely available at <ext-link ext-link-type="uri" xlink:href="https://rhpc.nki.nl/sites/shiny/ABPEP/">https://rhpc.nki.nl/sites/shiny/ABPEP/</ext-link>. The code is available under GNU General public license from GitHub ( <ext-link ext-link-type="uri" xlink:href="https://github.com/jasminesmn/ABPEPserver">https://github.com/jasminesmn/ABPEPserver</ext-link>).</p>
  </notes>
  <notes>
    <title>Declarations</title>
    <notes id="FPar1">
      <title>Ethics approval and consent to participate</title>
      <p id="Par23">Not applicable.</p>
    </notes>
    <notes id="FPar2">
      <title>Consent for publication</title>
      <p id="Par24">Not applicable.</p>
    </notes>
    <notes id="FPar3" notes-type="COI-statement">
      <title>Competing interests</title>
      <p id="Par25">Authors declare no competing interests.</p>
    </notes>
  </notes>
  <ref-list id="Bib1">
    <title>References</title>
    <ref id="CR1">
      <label>1.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Andreatta</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Nielsen</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>Gapped sequence alignment using artificial neural networks: application to the MHC class I system</article-title>
        <source>Bioinformatics</source>
        <year>2016</year>
        <volume>32</volume>
        <fpage>511</fpage>
        <lpage>517</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btv639</pub-id>
        <?supplied-pmid 26515819?>
        <pub-id pub-id-type="pmid">26515819</pub-id>
      </element-citation>
    </ref>
    <ref id="CR2">
      <label>2.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bonaventura</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Shekarian</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Alcazer</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Valladeau-Guilemond</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Valsesia-Wittmann</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Amigorena</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Caux</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Depil</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>Cold Tumors: A Therapeutic Challenge for Immunotherapy</article-title>
        <source>Front Immunol</source>
        <year>2019</year>
        <volume>10</volume>
        <fpage>168</fpage>
        <pub-id pub-id-type="doi">10.3389/fimmu.2019.00168</pub-id>
        <?supplied-pmid 30800125?>
        <pub-id pub-id-type="pmid">30800125</pub-id>
      </element-citation>
    </ref>
    <ref id="CR3">
      <label>3.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Cao</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Cui Zhou</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Hu</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Lih</surname>
            <given-names>TM</given-names>
          </name>
          <name>
            <surname>Savage</surname>
            <given-names>SR</given-names>
          </name>
          <name>
            <surname>Krug</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Clark</surname>
            <given-names>DJ</given-names>
          </name>
          <name>
            <surname>Schnaubelt</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>L</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Proteogenomic characterization of pancreatic ductal adenocarcinoma</article-title>
        <source>Cell</source>
        <year>2021</year>
        <volume>184</volume>
        <fpage>5031</fpage>
        <lpage>5052.e5026</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cell.2021.08.023</pub-id>
        <?supplied-pmid 34534465?>
        <pub-id pub-id-type="pmid">34534465</pub-id>
      </element-citation>
    </ref>
    <ref id="CR4">
      <label>4.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Chong</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Coukos</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Bassani-Sternberg</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>Identification of tumor antigens with immunopeptidomics</article-title>
        <source>Nat Biotechnol</source>
        <year>2022</year>
        <volume>40</volume>
        <fpage>175</fpage>
        <lpage>188</lpage>
        <pub-id pub-id-type="doi">10.1038/s41587-021-01038-8</pub-id>
        <?supplied-pmid 34635837?>
        <pub-id pub-id-type="pmid">34635837</pub-id>
      </element-citation>
    </ref>
    <ref id="CR5">
      <label>5.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Clark</surname>
            <given-names>DJ</given-names>
          </name>
          <name>
            <surname>Dhanasekaran</surname>
            <given-names>SM</given-names>
          </name>
          <name>
            <surname>Petralia</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Pan</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Song</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Hu</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>da Veiga Leprevost</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Reva</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Lih</surname>
            <given-names>TM</given-names>
          </name>
          <name>
            <surname>Chang</surname>
            <given-names>HY</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma</article-title>
        <source>Cell</source>
        <year>2019</year>
        <volume>179</volume>
        <fpage>964</fpage>
        <lpage>983.e931</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cell.2019.10.007</pub-id>
        <?supplied-pmid 31675502?>
        <pub-id pub-id-type="pmid">31675502</pub-id>
      </element-citation>
    </ref>
    <ref id="CR6">
      <label>6.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>da Veiga Leprevost</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Haynes</surname>
            <given-names>SE</given-names>
          </name>
          <name>
            <surname>Avtonomov</surname>
            <given-names>DM</given-names>
          </name>
          <name>
            <surname>Chang</surname>
            <given-names>HY</given-names>
          </name>
          <name>
            <surname>Shanmugam</surname>
            <given-names>AK</given-names>
          </name>
          <name>
            <surname>Mellacheruvu</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Kong</surname>
            <given-names>AT</given-names>
          </name>
          <name>
            <surname>Nesvizhskii</surname>
            <given-names>AI</given-names>
          </name>
        </person-group>
        <article-title>Philosopher: a versatile toolkit for shotgun proteomics data analysis</article-title>
        <source>Nat Methods</source>
        <year>2020</year>
        <volume>17</volume>
        <fpage>869</fpage>
        <lpage>870</lpage>
        <pub-id pub-id-type="doi">10.1038/s41592-020-0912-y</pub-id>
        <?supplied-pmid 32669682?>
        <pub-id pub-id-type="pmid">32669682</pub-id>
      </element-citation>
    </ref>
    <ref id="CR7">
      <label>7.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Dou</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Kawaler</surname>
            <given-names>EA</given-names>
          </name>
          <name>
            <surname>Cui Zhou</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Gritsenko</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Blumenberg</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Karpova</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Petyuk</surname>
            <given-names>VA</given-names>
          </name>
          <name>
            <surname>Savage</surname>
            <given-names>SR</given-names>
          </name>
          <name>
            <surname>Satpathy</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Proteogenomic Characterization of Endometrial Carcinoma</article-title>
        <source>Cell</source>
        <year>2020</year>
        <volume>180</volume>
        <fpage>729</fpage>
        <lpage>748.e726</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cell.2020.01.026</pub-id>
        <?supplied-pmid 32059776?>
        <pub-id pub-id-type="pmid">32059776</pub-id>
      </element-citation>
    </ref>
    <ref id="CR8">
      <label>8.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Edwards</surname>
            <given-names>NJ</given-names>
          </name>
          <name>
            <surname>Oberti</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Thangudu</surname>
            <given-names>RR</given-names>
          </name>
          <name>
            <surname>Cai</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>McGarvey</surname>
            <given-names>PB</given-names>
          </name>
          <name>
            <surname>Jacob</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Madhavan</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Ketchum</surname>
            <given-names>KA</given-names>
          </name>
        </person-group>
        <article-title>The CPTAC Data Portal: A Resource for Cancer Proteomics Research</article-title>
        <source>J Proteome Res</source>
        <year>2015</year>
        <volume>14</volume>
        <fpage>2707</fpage>
        <lpage>2713</lpage>
        <pub-id pub-id-type="doi">10.1021/pr501254j</pub-id>
        <?supplied-pmid 25873244?>
        <pub-id pub-id-type="pmid">25873244</pub-id>
      </element-citation>
    </ref>
    <ref id="CR9">
      <label>9.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Gao</surname>
            <given-names>Q</given-names>
          </name>
          <name>
            <surname>Zhu</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Dong</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Shi</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Song</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Dong</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>Y</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma</article-title>
        <source>Cell</source>
        <year>2019</year>
        <volume>179</volume>
        <fpage>561</fpage>
        <lpage>577.e522</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cell.2019.08.052</pub-id>
        <?supplied-pmid 31585088?>
        <pub-id pub-id-type="pmid">31585088</pub-id>
      </element-citation>
    </ref>
    <ref id="CR10">
      <label>10.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hiam-Galvez</surname>
            <given-names>KJ</given-names>
          </name>
          <name>
            <surname>Allen</surname>
            <given-names>BM</given-names>
          </name>
          <name>
            <surname>Spitzer</surname>
            <given-names>MH</given-names>
          </name>
        </person-group>
        <article-title>Systemic immunity in cancer</article-title>
        <source>Nat Rev Cancer</source>
        <year>2021</year>
        <volume>21</volume>
        <fpage>345</fpage>
        <lpage>359</lpage>
        <pub-id pub-id-type="doi">10.1038/s41568-021-00347-z</pub-id>
        <?supplied-pmid 33837297?>
        <pub-id pub-id-type="pmid">33837297</pub-id>
      </element-citation>
    </ref>
    <ref id="CR11">
      <label>11.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Huang</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Savage</surname>
            <given-names>SR</given-names>
          </name>
          <name>
            <surname>Eguez</surname>
            <given-names>RV</given-names>
          </name>
          <name>
            <surname>Dou</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>da Veiga Leprevost</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Jaehnig</surname>
            <given-names>EJ</given-names>
          </name>
          <name>
            <surname>Lei</surname>
            <given-names>JT</given-names>
          </name>
          <name>
            <surname>Wen</surname>
            <given-names>B</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma</article-title>
        <source>Cancer Cell</source>
        <year>2021</year>
        <volume>39</volume>
        <fpage>361</fpage>
        <lpage>379.e316</lpage>
        <pub-id pub-id-type="doi">10.1016/j.ccell.2020.12.007</pub-id>
        <?supplied-pmid 33417831?>
        <pub-id pub-id-type="pmid">33417831</pub-id>
      </element-citation>
    </ref>
    <ref id="CR12">
      <label>12.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>McDermott</surname>
            <given-names>JE</given-names>
          </name>
          <name>
            <surname>Arshad</surname>
            <given-names>OA</given-names>
          </name>
          <name>
            <surname>Petyuk</surname>
            <given-names>VA</given-names>
          </name>
          <name>
            <surname>Fu</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Gritsenko</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Clauss</surname>
            <given-names>TR</given-names>
          </name>
          <name>
            <surname>Moore</surname>
            <given-names>RJ</given-names>
          </name>
          <name>
            <surname>Schepmoes</surname>
            <given-names>AA</given-names>
          </name>
          <name>
            <surname>Zhao</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Monroe</surname>
            <given-names>ME</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Proteogenomic Characterization of Ovarian HGSC Implicates Mitotic Kinases, Replication Stress in Observed Chromosomal Instability</article-title>
        <source>Cell Rep Med</source>
        <year>2020</year>
        <volume>1</volume>
        <fpage>100004</fpage>
        <pub-id pub-id-type="doi">10.1016/j.xcrm.2020.100004</pub-id>
        <?supplied-pmid 32529193?>
        <pub-id pub-id-type="pmid">32529193</pub-id>
      </element-citation>
    </ref>
    <ref id="CR13">
      <label>13.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Pataskar</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Champagne</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Nagel</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Kenski</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Laos</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Michaux</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Pak</surname>
            <given-names>HS</given-names>
          </name>
          <name>
            <surname>Bleijerveld</surname>
            <given-names>OB</given-names>
          </name>
          <name>
            <surname>Mordente</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Navarro</surname>
            <given-names>JM</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Tryptophan depletion results in tryptophan-to-phenylalanine substitutants</article-title>
        <source>Nature</source>
        <year>2022</year>
        <volume>603</volume>
        <fpage>721</fpage>
        <lpage>727</lpage>
        <pub-id pub-id-type="doi">10.1038/s41586-022-04499-2</pub-id>
        <?supplied-pmid 35264796?>
        <pub-id pub-id-type="pmid">35264796</pub-id>
      </element-citation>
    </ref>
    <ref id="CR14">
      <label>14.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Satpathy</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Krug</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Jean Beltran</surname>
            <given-names>PM</given-names>
          </name>
          <name>
            <surname>Savage</surname>
            <given-names>SR</given-names>
          </name>
          <name>
            <surname>Petralia</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Kumar-Sinha</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Dou</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Reva</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Kane</surname>
            <given-names>MH</given-names>
          </name>
          <name>
            <surname>Avanessian</surname>
            <given-names>SC</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A proteogenomic portrait of lung squamous cell carcinoma</article-title>
        <source>Cell</source>
        <year>2021</year>
        <volume>184</volume>
        <fpage>4348</fpage>
        <lpage>4371.e4340</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cell.2021.07.016</pub-id>
        <?supplied-pmid 34358469?>
        <pub-id pub-id-type="pmid">34358469</pub-id>
      </element-citation>
    </ref>
    <ref id="CR15">
      <label>15.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Schumacher</surname>
            <given-names>TN</given-names>
          </name>
          <name>
            <surname>Schreiber</surname>
            <given-names>RD</given-names>
          </name>
        </person-group>
        <article-title>Neoantigens in cancer immunotherapy</article-title>
        <source>Science</source>
        <year>2015</year>
        <volume>348</volume>
        <fpage>69</fpage>
        <lpage>74</lpage>
        <pub-id pub-id-type="doi">10.1126/science.aaa4971</pub-id>
        <?supplied-pmid 25838375?>
        <pub-id pub-id-type="pmid">25838375</pub-id>
      </element-citation>
    </ref>
    <ref id="CR16">
      <label>16.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tan</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Zhu</surname>
            <given-names>X</given-names>
          </name>
        </person-group>
        <article-title>Cancer immunotherapy: Pros, cons and beyond</article-title>
        <source>Biomed Pharmacother</source>
        <year>2020</year>
        <volume>124</volume>
        <fpage>109821</fpage>
        <pub-id pub-id-type="doi">10.1016/j.biopha.2020.109821</pub-id>
        <?supplied-pmid 31962285?>
        <pub-id pub-id-type="pmid">31962285</pub-id>
      </element-citation>
    </ref>
    <ref id="CR17">
      <label>17.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tan</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Jian</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Wan</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Ouyang</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Xie</surname>
            <given-names>L</given-names>
          </name>
        </person-group>
        <article-title>dbPepNeo: a manually curated database for human tumor neoantigen peptides</article-title>
        <source>Database (Oxford)</source>
        <year>2020</year>
        <volume>2020</volume>
        <fpage>baaa004</fpage>
        <pub-id pub-id-type="doi">10.1093/database/baaa004</pub-id>
        <?supplied-pmid 32090262?>
        <pub-id pub-id-type="pmid">32090262</pub-id>
      </element-citation>
    </ref>
    <ref id="CR18">
      <label>18.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Vigneron</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Stroobant</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Van den Eynde</surname>
            <given-names>BJ</given-names>
          </name>
          <name>
            <surname>van der Bruggen</surname>
            <given-names>P</given-names>
          </name>
        </person-group>
        <article-title>Database of T cell-defined human tumor antigens: the 2013 update</article-title>
        <source>Cancer Immun</source>
        <year>2013</year>
        <volume>13</volume>
        <fpage>15</fpage>
        <?supplied-pmid 23882160?>
        <pub-id pub-id-type="pmid">23882160</pub-id>
      </element-citation>
    </ref>
    <ref id="CR19">
      <label>19.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Waldman</surname>
            <given-names>AD</given-names>
          </name>
          <name>
            <surname>Fritz</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>Lenardo</surname>
            <given-names>MJ</given-names>
          </name>
        </person-group>
        <article-title>A guide to cancer immunotherapy: from T cell basic science to clinical practice</article-title>
        <source>Nat Rev Immunol</source>
        <year>2020</year>
        <volume>20</volume>
        <fpage>651</fpage>
        <lpage>668</lpage>
        <pub-id pub-id-type="doi">10.1038/s41577-020-0306-5</pub-id>
        <?supplied-pmid 32433532?>
        <pub-id pub-id-type="pmid">32433532</pub-id>
      </element-citation>
    </ref>
    <ref id="CR20">
      <label>20.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>LB</given-names>
          </name>
          <name>
            <surname>Karpova</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Gritsenko</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Kyle</surname>
            <given-names>JE</given-names>
          </name>
          <name>
            <surname>Cao</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Rykunov</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Colaprico</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Rothstein</surname>
            <given-names>JH</given-names>
          </name>
          <name>
            <surname>Hong</surname>
            <given-names>R</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Proteogenomic and metabolomic characterization of human glioblastoma</article-title>
        <source>Cancer Cell</source>
        <year>2021</year>
        <volume>39</volume>
        <fpage>509</fpage>
        <lpage>528.e520</lpage>
        <pub-id pub-id-type="doi">10.1016/j.ccell.2021.01.006</pub-id>
        <?supplied-pmid 33577785?>
        <pub-id pub-id-type="pmid">33577785</pub-id>
      </element-citation>
    </ref>
    <ref id="CR21">
      <label>21</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yi</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Liao</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Wen</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Dou</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Savage</surname>
            <given-names>SR</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>B</given-names>
          </name>
        </person-group>
        <article-title>caAtlas: An immunopeptidome atlas of human cancer</article-title>
        <source>iScience</source>
        <year>2021</year>
        <volume>24</volume>
        <fpage>103107</fpage>
        <pub-id pub-id-type="doi">10.1016/j.isci.2021.103107</pub-id>
        <?supplied-pmid 34622160?>
        <pub-id pub-id-type="pmid">34622160</pub-id>
      </element-citation>
    </ref>
    <ref id="CR22">
      <label>22</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Chitkushev</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Olsen</surname>
            <given-names>LR</given-names>
          </name>
          <name>
            <surname>Keskin</surname>
            <given-names>DB</given-names>
          </name>
          <name>
            <surname>Brusic</surname>
            <given-names>V</given-names>
          </name>
        </person-group>
        <article-title>TANTIGEN 2.0: a knowledge base of tumor T cell antigens and epitopes</article-title>
        <source>BMC Bioinformatics</source>
        <year>2021</year>
        <volume>22</volume>
        <fpage>40</fpage>
        <pub-id pub-id-type="doi">10.1186/s12859-021-03962-7</pub-id>
        <?supplied-pmid 33849445?>
        <pub-id pub-id-type="pmid">33849445</pub-id>
      </element-citation>
    </ref>
    <ref id="CR23">
      <label>23.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Lu</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Qin</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Gao</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Tao</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Su</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Zhong</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>Neoantigen: A New Breakthrough in Tumor Immunotherapy</article-title>
        <source>Front Immunol</source>
        <year>2021</year>
        <volume>12</volume>
        <fpage>672356</fpage>
        <pub-id pub-id-type="doi">10.3389/fimmu.2021.672356</pub-id>
        <?supplied-pmid 33936118?>
        <pub-id pub-id-type="pmid">33936118</pub-id>
      </element-citation>
    </ref>
  </ref-list>
</back>
<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName A++V2.4.dtd?>
<?SourceDTD.Version 2.4?>
<?ConverterInfo.XSLTName springer2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id>
    <journal-id journal-id-type="iso-abbrev">BMC Cancer</journal-id>
    <journal-title-group>
      <journal-title>BMC Cancer</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1471-2407</issn>
    <publisher>
      <publisher-name>BioMed Central</publisher-name>
      <publisher-loc>London</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10239192</article-id>
    <article-id pub-id-type="publisher-id">10970</article-id>
    <article-id pub-id-type="doi">10.1186/s12885-023-10970-8</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Database</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>ABPEPserver: a web application for documentation and analysis of substitutants</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" corresp="yes" equal-contrib="yes">
        <name>
          <surname>Pataskar</surname>
          <given-names>Abhijeet</given-names>
        </name>
        <address>
          <email>a.pataskar@nki.nl</email>
        </address>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author" equal-contrib="yes">
        <name>
          <surname>Montenegro Navarro</surname>
          <given-names>Jasmine</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1">1</xref>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2848-2473</contrib-id>
        <name>
          <surname>Agami</surname>
          <given-names>Reuven</given-names>
        </name>
        <address>
          <email>r.agami@nki.nl</email>
        </address>
        <xref ref-type="aff" rid="Aff1">1</xref>
        <xref ref-type="aff" rid="Aff2">2</xref>
      </contrib>
      <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.430814.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 0674 1393</institution-id><institution>Division of Oncogenomics, </institution><institution>Oncode Institute, The Netherlands Cancer Institute, </institution></institution-wrap>Plesmanlaan 121, 1066CX Amsterdam, the Netherlands </aff>
      <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.5645.2</institution-id><institution-id institution-id-type="ISNI">000000040459992X</institution-id><institution>Erasmus MC, Department of Genetics, </institution><institution>Rotterdam University, </institution></institution-wrap>Rotterdam, the Netherlands </aff>
    </contrib-group>
    <pub-date pub-type="epub">
      <day>3</day>
      <month>6</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>3</day>
      <month>6</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2023</year>
    </pub-date>
    <volume>23</volume>
    <elocation-id>502</elocation-id>
    <history>
      <date date-type="received">
        <day>4</day>
        <month>5</month>
        <year>2022</year>
      </date>
      <date date-type="accepted">
        <day>16</day>
        <month>5</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2023</copyright-statement>
      <license>
        <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p>
      </license>
    </permissions>
    <abstract id="Abs1">
      <sec>
        <title>Background</title>
        <p id="Par1">Cancer immunotherapy is implemented by identifying antigens that are presented on the cell surface of cancer cells and illicit T-cell response (Schumacher and Schreiber, Science 348:69–74, 2015; Waldman et al., Nat Rev Immunol 20:651–668, 2020; Zhang et al., Front Immunol 12:672,356, 2021b). Classical candidates of such antigens are the peptides resulting from genetic alterations and are named “neoantigen" (Schumacher and Schreiber, Science 348:69–74, 2015). Neoantigens have been widely catalogued across several human cancer types (Tan et al., Database (Oxford) 2020;2020b; Vigneron et al., Cancer Immun 13:15, 2013; Yi et al., iScience 24:103,107, 2021; Zhang et al., BMC Bioinformatics 22:40, 2021a). Recently, a new class of inducible antigens has been identified, namely Substitutants, that are produced as a result of aberrant protein translation (Pataskar et al., Nature 603:721–727, 2022).</p>
      </sec>
      <sec>
        <title>Main</title>
        <p id="Par2">Catalogues of Substitutant expression across human cancer types, their specificity and association to gene expression signatures remain elusive for the scientific community's access. As a solution, we present ABPEPserver, an online database and analytical platform that can visualize a large-scale tumour proteomics analysis of Substitutant expression across eight tumour types sourced from the CPTAC database (Edwards et al., J Proteome Res 14:2707–2713, 2015). Functionally, ABPEPserver offers the analysis of gene-association signatures of Substitutant peptides, a comparison of enrichment between tumour and tumour-adjacent normal tissues, and a list of peptides that serve as candidates for immunotherapy design. ABPEPserver will significantly enhance the exploration of aberrant protein production in human cancer, as exemplified in a case study.</p>
      </sec>
      <sec>
        <title>Conclusion</title>
        <p id="Par3">ABPEPserver is designed on an R SHINY platform to catalogue Substitutant peptides in human cancer. The application is available at <ext-link ext-link-type="uri" xlink:href="https://rhpc.nki.nl/sites/shiny/ABPEP/">https://rhpc.nki.nl/sites/shiny/ABPEP/</ext-link>. The code is available under GNU General public license from GitHub (<ext-link ext-link-type="uri" xlink:href="https://github.com/jasminesmn/ABPEPserver">https://github.com/jasminesmn/ABPEPserver</ext-link>).</p>
      </sec>
      <sec>
        <title>Supplementary Information</title>
        <p>The online version contains supplementary material available at 10.1186/s12885-023-10970-8.</p>
      </sec>
    </abstract>
    <kwd-group xml:lang="en">
      <title>Keywords</title>
      <kwd>Substitutants</kwd>
      <kwd>Codon reassignment</kwd>
      <kwd>Translation</kwd>
      <kwd>Cancer</kwd>
      <kwd>Immunotherapy</kwd>
    </kwd-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004622</institution-id>
            <institution>KWF Kankerbestrijding</institution>
          </institution-wrap>
        </funding-source>
        <award-id>13647</award-id>
        <principal-award-recipient>
          <name>
            <surname>Agami</surname>
            <given-names>Reuven</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
    </funding-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100011199</institution-id>
            <institution>FP7 Ideas: European Research Council</institution>
          </institution-wrap>
        </funding-source>
        <award-id>832844</award-id>
        <principal-award-recipient>
          <name>
            <surname>Agami</surname>
            <given-names>Reuven</given-names>
          </name>
        </principal-award-recipient>
      </award-group>
    </funding-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>issue-copyright-statement</meta-name>
        <meta-value>© BioMed Central Ltd., part of Springer Nature 2023</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="Sec1">
    <title>Background</title>
    <p id="Par4">Cancer immunotherapy has improved cancer patients' treatment possibilities, especially those with metastatic spread [<xref ref-type="bibr" rid="CR19">19</xref>]. Although the success, the clinical outcome of immunotherapy is not consistent both within and across cancer entities. A sufficient infiltration into the tumour microenvironment and activation of effector T-cells against cancer cells can be seen as predictors for responses to T-cell-based immunotherapies [<xref ref-type="bibr" rid="CR15">15</xref>–<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR21">21</xref>–<xref ref-type="bibr" rid="CR23">23</xref>]. However, cancer cells have developed multiple mechanisms to inhibit anticancer immunity's activity, effecting antigen presentation on Human Leukocyte Antigen (HLA) class I receptor molecules [<xref ref-type="bibr" rid="CR10">10</xref>].</p>
    <p id="Par5">Based on the responsiveness to immunotherapy, a tumour type could be classified as “hot”, i.e. responsive and “cold”, i.e. non-responsive tumours [<xref ref-type="bibr" rid="CR2">2</xref>]. A critical delineator between these tumour-types is the identification of presentable antigens that harbour the ability to elicit T-cell responses [<xref ref-type="bibr" rid="CR4">4</xref>]. Recently, a new class of antigens were identified, namely Substitutants, which are produced as a result of aberrant translation consequential of T cell infiltration associated endogenous tryptophan depletion [<xref ref-type="bibr" rid="CR13">13</xref>] (Fig. <xref rid="Fig1" ref-type="fig">1</xref>A). Substitutants are defined as peptides arising because of Tryptophan to Phenylalanine substitution in cancer cells as a result of tryptophan shortage. Importantly, Substitutant peptides harbour immunotherapeutic potential owing to their ability to elicit T cell responses [<xref ref-type="bibr" rid="CR13">13</xref>] (Fig. <xref rid="Fig1" ref-type="fig">1</xref>B). Hence, it is not only necessary to correctly identify and catalogue presentable substitutants across multiple human tumour-types, but it is also essential that we understand molecular pathways that enrich their production and presentation.<fig id="Fig1"><label>Fig. 1</label><caption><p>Substitutants as novel cancer antigens. <bold>A</bold> A flowchart depicting the pathways in cancer cells leading to the generation of W &gt; F substitutants. <bold>B</bold> A model describing the mechanisms leading to the presentation of substitutant antigens and consequential T cell killing of cancer cells</p></caption><graphic xlink:href="12885_2023_10970_Fig1_HTML" id="MO1"/></fig></p>
    <p id="Par6">To identify and characterize such substitutant peptides, we undertook a large-scale proteomic analysis of multiple cancer types sourced from the CPTAC consortium [<xref ref-type="bibr" rid="CR8">8</xref>]. To make this analysis more accessible to the scientific community, we developed an online database called ABPEPserver, which harbours substitutant information from eight independent human tumour types, namely Lung Squamous Cell Carcinoma (LSCC, [<xref ref-type="bibr" rid="CR14">14</xref>]), Clear Cell Renal Cell Carcinoma (CCRCC, [<xref ref-type="bibr" rid="CR5">5</xref>]), Glioblastoma (GBM, [<xref ref-type="bibr" rid="CR20">20</xref>]), Head and Neck Squamous Cell Carcinoma (HNSCC, [<xref ref-type="bibr" rid="CR11">11</xref>]), Hepatocellular Carcinoma (HCC, [<xref ref-type="bibr" rid="CR9">9</xref>]), Ovarian Sereous Cystadenocarcinoma (OVSCC, [<xref ref-type="bibr" rid="CR12">12</xref>]), Pancreatic Ductal Carcinoma (PDA, [<xref ref-type="bibr" rid="CR3">3</xref>]), Uterine Corpus Endometrial Carcinoma (UCEC, [<xref ref-type="bibr" rid="CR7">7</xref>]). ABPEPserver provides background information on the substitutant peptides and their analyzed cancer type description, a comparative analysis of substitutant expression in tumours and tumour-adjacent normal tissues, and downloadable links of text files harbouring this information. These substitutant peptides can then be used for predicting neoepitopes for potential immunotherapy tests. Altogether, ABPEPserver is an ease-of-access web tool useful towards designing immunotherapeutic substitutant candidates (Fig. <xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2"><label>Fig. 2</label><caption><p>Design of ABPEPserver. A model describes the ABPEPserver. The server offers a web interface for easy data accessibility, analytical tools for biological interpretation, and the possibility of downloading relevant data in text format. The database was designed in MySQL, uses W-peptide counts, Gene expression profiles downloaded from the PDC commons Databases, identified substitutant peptides and Gene cluster data information for eight cancer types, sourcing data from 911 tumours and 558 tumour-adjacent normal tissue</p></caption><graphic xlink:href="12885_2023_10970_Fig2_HTML" id="MO2"/></fig></p>
  </sec>
  <sec id="Sec2">
    <title>Construction and content</title>
    <sec id="Sec3">
      <title>Proteomic analysis of substitutant peptide expression</title>
      <p id="Par7">As previously published, a reanalysis of substituants peptide expression was undertaken [<xref ref-type="bibr" rid="CR13">13</xref>]. Briefly, Philosopher pipeline was used to detect endogenous substituants in the large-scale proteomics dataset with the same parameters as previously published [<xref ref-type="bibr" rid="CR6">6</xref>].</p>
      <p id="Par8">Mass spectrometry-derived processed spectra (mzML) files for all independent cancer types were obtained from the CPTAC database [<xref ref-type="bibr" rid="CR8">8</xref>]. The database of protein sequences was prepared in one of two ways. First, the human proteome with all instances of tryptophan amino acids in the proteome changed to all other amino acids except Arginine and Lysine was used as a database in the scan – referred to as database 1(fully substitutant). Second, to optimize true positives, we generated a second database (optimized database) which includes the canonical human proteome (UniPROT) with the substitutant tryptic peptides (length &gt; 5 &amp; &lt; 50 amino acids) spanning tryptophan residue and tryptophan substituted to all other amino acids. The analysis of both these databases is presented separately on the server. Additional details on the FASTA file are available on the GITHUB page and the description section on the server. Briefly, MSFragger searches the mzML spectral files against the custom database for peptide detection with the following parameters; Precursor mass lower: − 20 ppm, Precursor mass upper: 20 ppm, precursor mass tolerance: 20 ppm, calibrate mass: True, Deisotoping: True, mass offset: False, isotope error: Standard, digestion: Strictly tryptic (Max. missed cleavage: 2), Variable modifications: 15.99490 M 3, 42.01060 [^ 1, 144.1021 n^ 1, 144.1021 S 1, Min Length: 7, Max Length: 50, digest mass range: 500:5000 Daltons, Max Charge: 2, remove precursor range: − 1.5, 1.5, topN peaks: 300, minimum peaks: 15, precursor range: 1:6, add Cysteine: 57.021464, add Lysine: 229.162932, among other basic parameters (Supplementary Table <xref rid="MOESM2" ref-type="media">1</xref>). Next, PeptideProphet validates detected peptides with the following parameters; accmass: TRUE, decoyprobs: TRUE, expectScore: TRUE, Glycosylation: FALSE, ICAT: FALSE, masswidth: 5, minimum probability after first pass of a peptide: 0.9, minimum number of NTT in a peptide: 2, among other parameters (Supplementary Table <xref rid="MOESM2" ref-type="media">1</xref>). Isobaric quantification was then undertaken the following parameters (bestPSM: TRUE, level: 2, minProb 0.7, ion purity cut-off: 0.5, tolerance: 20 ppm, among other parameters (Supplementary Table <xref rid="MOESM2" ref-type="media">1</xref>). Next, to only retain confident peptides, peptides were filtered using stringent False Discovery Rate (FDR) filtering. The following parameters were used for FDR filtering; FDR &lt; 0.01, peptideProbability: 0.7, among other parameters (Supplementary Table <xref rid="MOESM2" ref-type="media">1</xref>). Next, TMT-integrator was used to create integrated reports with isobaric quantification across all samples with the following parameters (retention time normalization: False, minimum peptide probability on top of FDR filtering: 0.9, among other parameters (Supplementary Table <xref rid="MOESM2" ref-type="media">1</xref>).</p>
      <p id="Par9">Substitutant peptides were fetched from the reports of TMT Integrator (version 3.1.0). Using a R-script, peptides with a log2-transformed intensity score above 0 in a sample were observed as positively detected peptides in that sample. As described before [<xref ref-type="bibr" rid="CR13">13</xref>], for intra-tumour type analysis a filter for the maximum number of samples was applied to retain peptides with higher specificity in expression, except for W &gt; F substitutants due to their exclusive significant and specific distribution wherever significant. All tumour types have been demonstrated to be exclusive with the analysis of database 1 [<xref ref-type="bibr" rid="CR13">13</xref>], while GBM, UCEC, and PDA did not show this exclusivity in the analysis of database 2. This optimizes the signal for gene expression correlation analysis. Furthermore, this script was used to plot bar plots depicting the cumulative number of tryptophan substitutants detected in the scans.</p>
      <p id="Par10">Gene expression data was downloaded in GCT format from PDC database. The counts of W-substitutants were combined for each sample with gene expression profiles. PERL scripts were designed to count the number of substitutants when a gene is lowly expressed (intensity &lt; 0) or highly expressed (intensity &gt; 0). <italic>P</italic>-values for comparison are calculated using Wilcoxen t-test.</p>
    </sec>
    <sec id="Sec4">
      <title>Data sources</title>
      <p id="Par11">Eight independent human tumour-types, namely Lung Squamous Cell Carcinoma (LSCC, [<xref ref-type="bibr" rid="CR14">14</xref>]), Clear Cell Renal Cell Carcinoma (CCRCC, [<xref ref-type="bibr" rid="CR5">5</xref>]), Glioblastoma (GBM, [<xref ref-type="bibr" rid="CR20">20</xref>]), Head and Neck Squamous Cell Carcinoma (HNSCC, [<xref ref-type="bibr" rid="CR11">11</xref>]), Hepatocellular Carcinoma (HCC, [<xref ref-type="bibr" rid="CR9">9</xref>]), Ovarian Serous Cystadenocarcinoma (OVSCC, [<xref ref-type="bibr" rid="CR12">12</xref>]), Pancreatic Ductal Carcinoma (PDA, [<xref ref-type="bibr" rid="CR3">3</xref>]), Uterine Corpus Endometrial Carcinoma (UCEC, [<xref ref-type="bibr" rid="CR7">7</xref>]), were analysed to generate ABPEPserver database (Table <xref rid="Tab1" ref-type="table">1</xref>) [<xref ref-type="bibr" rid="CR1">1</xref>]. CPTAC IDS of the datasets are provided in Table<xref rid="Tab1" ref-type="table">1</xref> and Supplementary Table <xref rid="MOESM3" ref-type="media">2</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>This table details the tumour types used to build ABPEPserver, with the information on identified substitutants and the number of tumours and adjacent normal tissues used to build the analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Cancer type</th><th align="left">PDC study ID</th><th align="left">Substitutants</th><th align="left"># Tumor<break/>samples</th><th align="left"># Normal samples</th></tr></thead><tbody><tr><td align="left">Clear Cell Renal Carcinoma</td><td align="left">PDC000127</td><td align="left">3623</td><td align="left">110</td><td align="left">84</td></tr><tr><td align="left">Glioblastoma</td><td align="left">PDC000204</td><td align="left">3978</td><td align="left">100</td><td align="left">10</td></tr><tr><td align="left">Head and neck Squamous Cell Carcinoma</td><td align="left">PDC000221</td><td align="left">3212</td><td align="left">105</td><td align="left">53</td></tr><tr><td align="left">Hepatocellular Carcinoma</td><td align="left">PDC000198</td><td align="left">9787</td><td align="left">165</td><td align="left">165</td></tr><tr><td align="left">Lung Squamous Cell Carcinoma</td><td align="left">PDC000234</td><td align="left">8237</td><td align="left">110</td><td align="left">101</td></tr><tr><td align="left">Ovarian Serous Cystadenocarcinoma</td><td align="left">PDC000110</td><td align="left">892</td><td align="left">84</td><td align="left">22</td></tr><tr><td align="left">Pancreatic Ductal Adenocarcinoma</td><td align="left">PDC000270</td><td align="left">3440</td><td align="left">137</td><td align="left">74</td></tr><tr><td align="left">Uterine Corpus Endometrial Carcinoma</td><td align="left">PDC000125</td><td align="left">4329</td><td align="left">100</td><td align="left">49</td></tr></tbody></table></table-wrap></p>
    </sec>
    <sec id="Sec5">
      <title>Design of database and web tools</title>
      <p id="Par12">A MySQL database was created to efficiently organize output data and avoid storage difficulties of multiple large files. With a database, data is efficiently stored and easily retrievable. For each cancer type, we stored substitutant counts. We identified individual substitutant peptides and gene cluster data from the proteomic analysis and associated gene expression. Data for tumour and adjacent normal tissue samples are made distinguishable for comparison.</p>
    </sec>
    <sec id="Sec6">
      <title>Implementation</title>
      <p id="Par13">ABPEPserver is a R/Shiny application which allows users to interact with and visualize our data and analysis. We implemented the R package RMySQL 0.10.23 to connect our database to the application.</p>
      <p id="Par14">Users are provided with background scientific information, methods and cancer types used in the study on the home page of the ABPEPserver. Users are provided then two options for using the web tools, viz. Analyze and tryptophan to phenylalanine (W &gt; F) Substitutants. In the “Analyze” module, the user can explore the enrichment of substitutants and their association with molecular gene expression signatures. On the other hand, the “W &gt; F Substitutants” module can be employed to browse individual substitutants in multiple cancer types and tumour vs adjacent normal tissue expression. Here, the information on the database used to detect the peptide is also added. The corresponding files of this module are downloadable.</p>
    </sec>
  </sec>
  <sec id="Sec7">
    <title>Utility and discussion</title>
    <sec id="Sec8">
      <title>Description of utility</title>
      <p id="Par15">ABPEPserver is a web database that serves as a platform to identify and characterize the expression of substitutants, a recently identified class of aberrant proteins with immunotherapeutic potential, across various human cancer types. In addition, ABPEPserver allows the analysis of the association of molecular gene expression signatures to the enrichment of substituants. As an example, such analysis was demonstrated to be essential for pinpointing the role of T-cell infiltration and direct causal proteins (such as IDO1) in the expression of W &gt; F substitutant peptides (Fig. <xref rid="Fig2" ref-type="fig">2</xref>) [<xref ref-type="bibr" rid="CR13">13</xref>]. This shows that the expression of substitutant peptides is regulated by IDO1 expression, which is induced via the T-cell infiltration pathway.</p>
      <p id="Par16">Furthermore, ABPEPserver displays enrichment differences of substitutant peptides in tumours and tumour-adjacent normal tissues, an analysis that can be utilized for underpinning cancer-specific underlying mechanisms. Lastly, downloadable text files from the ABPEPserver can be used to identify common cancer-specific substitutants that can provide the foundation for predicting neoepitopes for a wide-ranging immunotherapeutic application. Altogether, ABPEPserver provides detailed information on the identity of the substitutants, their cancer-specific expression and immunotherapeutic potential.</p>
    </sec>
    <sec id="Sec9">
      <title>User interface</title>
      <sec id="Sec10">
        <title>Main page</title>
        <p id="Par17">The main page of ABPEPserver displays relevant information, methods in detail and cancer types used in the analysis in the construction of ABPEPserver along with supplementary information on each cancer type (Supplementary Fig. <xref rid="MOESM1" ref-type="media">1</xref>A).</p>
      </sec>
      <sec id="Sec11">
        <title>Analyze module</title>
        <p id="Par18">The “Analyze” module allows the user to select the cancer type and database of interest and plot Barplots, scatter-contour plots and Violin plots for analytical purposes (Supplementary Fig. <xref rid="MOESM1" ref-type="media">1</xref>B). Barplots allow the display of various types of W-substitutants and their relative enrichment concerning each other. Scatter contour plots allow the association analysis of all proteins to the number of substitutants. Violin plots allow the analysis of individual protein association with the number of substitutants. For example, IDO1 expression was associated with substitutant peptide expression using this analysis (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). IDO1 is an enzyme that catabolizes Tryptophan molecules in the cell; hence, the association of IDO1 expression with substitutants is biologically meaningful. Hence, Analyze module provide critical biological insights into the substitutant peptide expression and can be used by the users to design cancer-specific immunotherapy study.</p>
      </sec>
      <sec id="Sec12">
        <title>W &gt; F substitutants module</title>
        <p id="Par19">This module allows users to select the cancer type and database of interest and plot and download individual peptides for potential immunotherapeutic applications (Supplementary Fig. <xref rid="MOESM1" ref-type="media">1</xref>C). The utility of this module is demonstrated in a case study below.</p>
      </sec>
    </sec>
    <sec id="Sec13">
      <title>Case study: identification of immunocompetent substitutants using ABPEPserver</title>
      <p id="Par20">Using the “W &gt; F Substitutants” module for UCEC (Uterine Cancer) and the displayed scatter-plot, two example peptides ( fGHPAGK and SVLGCfK) were identified using fully substitutant database (database 1) and found to be expressed in a highly tumour-specific manner (73 tumours and 0 tumour-adjacent normal tissue, 45 tumours and 0 tumour-adjacent normal tissue respectively) (Fig. <xref rid="Fig3" ref-type="fig">3</xref>A). This tumour-specific expression implies that it is feasible to target these antigens specifically in cancerous tissues without harbouring any reactivity against normal cells if these peptides can present on the cell surface and bind to HLA molecules. Indeed, NETMHC [<xref ref-type="bibr" rid="CR1">1</xref>] based prediction shows that many combinations of these two peptides have potentially strong binding affinity to one or multiple HLA super-alleles (Fig. <xref rid="Fig3" ref-type="fig">3</xref>B-C). This analysis indicates that the discovered peptides potentially harbour strong immunotherapeutic potential and warrant experimental validation. Thus, ABPEPserver can be used to identify potential cancer-specific antigens for immunotherapeutic applications.<fig id="Fig3"><label>Fig. 3</label><caption><p>Case-study: Utility of ABPEPserver. <bold>A</bold> A scatter plot from ABPEPserver (W &gt; F Substitutants module) for UCEC (Uterine Cancer), depicting total occurrences in tumour tissue samples on X-axis and Total occurrences in adj. normal tissue samples on Y-axis. Identification of two peptides that are selected to be highly tumour-specifically expressed. The database used for this scatter plot is the fully substitutant database (database 1). <bold>B</bold>, <bold>C</bold> Tables displaying peptide combinations for the selected peptides in (A) that have HLA-binding ability to one or more HLA super alleles. Rank is displayed as inverse rank from NETMHC <sup>23</sup>analysis where peptides rank &lt; 1 are identified as strong binders and rank &gt; 1 &amp; rank &lt; 2 are identified as weak binders</p></caption><graphic xlink:href="12885_2023_10970_Fig3_HTML" id="MO3"/></fig></p>
    </sec>
    <sec id="Sec14">
      <title>Future outlook</title>
      <p id="Par21">In future, we plan to expand ABPEPserver functionality towards harbouring other kinds of aberrant peptides that are discovered, such as ribosomal-frameshift-associated chimeric peptides. In response to tryptophan shortage, it has been observed that ribosomes change the frame at the tryptophan-associated “TGG” codon, leading to the synthesis of W-chimera. Since W-chimera were only observed in cell-culture systems, it is important to analyze whether W-chimeras is also expressed in the eight cancer types analyzed here. If the expression is observed, the next pursuit is the association of gene expression pathways.</p>
    </sec>
  </sec>
  <sec id="Sec15">
    <title>Conclusions</title>
    <p id="Par22">We present ABPEPserver, a database of aberrant Substitutant peptides in human cancer. Substitutant peptides result from tryptophan to phenylalanine misincorporation events and are generated in human cancer due to T-cell infiltration and subsequent tryptophan depletion [<xref ref-type="bibr" rid="CR13">13</xref>]. The “Analyze” module of ABPEPserver allows exploration of gene expression signature of substitutant peptide expression in multiple human cancer types, organized as peptides detected in tumours and tumour-adjacent normal tissue. The W &gt; F “Substitutant” modules allow exploration of individual Substitutant peptides in multiple patient samples and have download features. The presented case study exemplifies that the substitutant peptides identified by ABPEPserver harbour immunotherapeutic potential. Hence, ABPEPserver is a valuable resource to the scientific community invested in anti-tumour immunotherapy development.</p>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Information</title>
    <sec id="Sec16">
      <p>
        <supplementary-material content-type="local-data" id="MOESM1">
          <media xlink:href="12885_2023_10970_MOESM1_ESM.pdf">
            <caption>
              <p><bold>Additional file 1: Supplementary Figure 1.</bold> Description: ABPEPserver design and modules. (A) Introduction Main page of ABPEPserver provides background information, methods and Cancer-types used for the development of the server. (B) User entry page of “Analyze module” wherein user can select cancer-type of interest and one of the three Analyze sub-modules (C) User entry page “W&gt;F Substitutant” peptides with browse function.</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="MOESM2">
          <media xlink:href="12885_2023_10970_MOESM2_ESM.xlsx">
            <caption>
              <p><bold>Additional file 2: Supplementary Table 1.</bold> Philosopher parameters used for scanning and detecting substitutant peptides in cancer proteomes.</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="MOESM3">
          <media xlink:href="12885_2023_10970_MOESM3_ESM.xlsx">
            <caption>
              <p><bold>Additional file 3: Supplementary Table 2.</bold> The table detailing publications associated to the analyzed data.</p>
            </caption>
          </media>
        </supplementary-material>
      </p>
    </sec>
  </sec>
</body>
<back>
  <fn-group>
    <fn>
      <p>
        <bold>Publisher’s Note</bold>
      </p>
      <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
    </fn>
    <fn>
      <p>Abhijeet Pataskar and Jasmine Montenegro Navarro contributed equally.</p>
    </fn>
  </fn-group>
  <ack>
    <title>Acknowledgements</title>
    <p>The authors would like to thank members of the Agami Group for their feedback. The authors would also like to thank Bhagyashree Joshi for help with the figures created with BioRender.com.</p>
  </ack>
  <notes notes-type="author-contribution">
    <title>Authors’ contributions</title>
    <p>AP designed the study and bioinformatics analysis. JMN helped with bioinformatics analysis and designed the server. RA designed and supervised the study. The author(s) read and approved the final manuscript.</p>
  </notes>
  <notes notes-type="funding-information">
    <title>Funding</title>
    <p>R.A. is supported by the Dutch cancer society (KWF projects 11037 and 13647), the European research council (ERC-2018-ADG—GA 832844), NWO computational grant (2021.034) and the AvL Foundation.</p>
  </notes>
  <notes notes-type="data-availability">
    <title>Availability of data and materials</title>
    <p>The application, data, and material are freely available at <ext-link ext-link-type="uri" xlink:href="https://rhpc.nki.nl/sites/shiny/ABPEP/">https://rhpc.nki.nl/sites/shiny/ABPEP/</ext-link>. The code is available under GNU General public license from GitHub ( <ext-link ext-link-type="uri" xlink:href="https://github.com/jasminesmn/ABPEPserver">https://github.com/jasminesmn/ABPEPserver</ext-link>).</p>
  </notes>
  <notes>
    <title>Declarations</title>
    <notes id="FPar1">
      <title>Ethics approval and consent to participate</title>
      <p id="Par23">Not applicable.</p>
    </notes>
    <notes id="FPar2">
      <title>Consent for publication</title>
      <p id="Par24">Not applicable.</p>
    </notes>
    <notes id="FPar3" notes-type="COI-statement">
      <title>Competing interests</title>
      <p id="Par25">Authors declare no competing interests.</p>
    </notes>
  </notes>
  <ref-list id="Bib1">
    <title>References</title>
    <ref id="CR1">
      <label>1.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Andreatta</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Nielsen</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>Gapped sequence alignment using artificial neural networks: application to the MHC class I system</article-title>
        <source>Bioinformatics</source>
        <year>2016</year>
        <volume>32</volume>
        <fpage>511</fpage>
        <lpage>517</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btv639</pub-id>
        <?supplied-pmid 26515819?>
        <pub-id pub-id-type="pmid">26515819</pub-id>
      </element-citation>
    </ref>
    <ref id="CR2">
      <label>2.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bonaventura</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Shekarian</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Alcazer</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Valladeau-Guilemond</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Valsesia-Wittmann</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Amigorena</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Caux</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Depil</surname>
            <given-names>S</given-names>
          </name>
        </person-group>
        <article-title>Cold Tumors: A Therapeutic Challenge for Immunotherapy</article-title>
        <source>Front Immunol</source>
        <year>2019</year>
        <volume>10</volume>
        <fpage>168</fpage>
        <pub-id pub-id-type="doi">10.3389/fimmu.2019.00168</pub-id>
        <?supplied-pmid 30800125?>
        <pub-id pub-id-type="pmid">30800125</pub-id>
      </element-citation>
    </ref>
    <ref id="CR3">
      <label>3.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Cao</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Cui Zhou</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Hu</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Lih</surname>
            <given-names>TM</given-names>
          </name>
          <name>
            <surname>Savage</surname>
            <given-names>SR</given-names>
          </name>
          <name>
            <surname>Krug</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Clark</surname>
            <given-names>DJ</given-names>
          </name>
          <name>
            <surname>Schnaubelt</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>L</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Proteogenomic characterization of pancreatic ductal adenocarcinoma</article-title>
        <source>Cell</source>
        <year>2021</year>
        <volume>184</volume>
        <fpage>5031</fpage>
        <lpage>5052.e5026</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cell.2021.08.023</pub-id>
        <?supplied-pmid 34534465?>
        <pub-id pub-id-type="pmid">34534465</pub-id>
      </element-citation>
    </ref>
    <ref id="CR4">
      <label>4.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Chong</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Coukos</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Bassani-Sternberg</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>Identification of tumor antigens with immunopeptidomics</article-title>
        <source>Nat Biotechnol</source>
        <year>2022</year>
        <volume>40</volume>
        <fpage>175</fpage>
        <lpage>188</lpage>
        <pub-id pub-id-type="doi">10.1038/s41587-021-01038-8</pub-id>
        <?supplied-pmid 34635837?>
        <pub-id pub-id-type="pmid">34635837</pub-id>
      </element-citation>
    </ref>
    <ref id="CR5">
      <label>5.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Clark</surname>
            <given-names>DJ</given-names>
          </name>
          <name>
            <surname>Dhanasekaran</surname>
            <given-names>SM</given-names>
          </name>
          <name>
            <surname>Petralia</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Pan</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Song</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Hu</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>da Veiga Leprevost</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Reva</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Lih</surname>
            <given-names>TM</given-names>
          </name>
          <name>
            <surname>Chang</surname>
            <given-names>HY</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma</article-title>
        <source>Cell</source>
        <year>2019</year>
        <volume>179</volume>
        <fpage>964</fpage>
        <lpage>983.e931</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cell.2019.10.007</pub-id>
        <?supplied-pmid 31675502?>
        <pub-id pub-id-type="pmid">31675502</pub-id>
      </element-citation>
    </ref>
    <ref id="CR6">
      <label>6.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>da Veiga Leprevost</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Haynes</surname>
            <given-names>SE</given-names>
          </name>
          <name>
            <surname>Avtonomov</surname>
            <given-names>DM</given-names>
          </name>
          <name>
            <surname>Chang</surname>
            <given-names>HY</given-names>
          </name>
          <name>
            <surname>Shanmugam</surname>
            <given-names>AK</given-names>
          </name>
          <name>
            <surname>Mellacheruvu</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Kong</surname>
            <given-names>AT</given-names>
          </name>
          <name>
            <surname>Nesvizhskii</surname>
            <given-names>AI</given-names>
          </name>
        </person-group>
        <article-title>Philosopher: a versatile toolkit for shotgun proteomics data analysis</article-title>
        <source>Nat Methods</source>
        <year>2020</year>
        <volume>17</volume>
        <fpage>869</fpage>
        <lpage>870</lpage>
        <pub-id pub-id-type="doi">10.1038/s41592-020-0912-y</pub-id>
        <?supplied-pmid 32669682?>
        <pub-id pub-id-type="pmid">32669682</pub-id>
      </element-citation>
    </ref>
    <ref id="CR7">
      <label>7.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Dou</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Kawaler</surname>
            <given-names>EA</given-names>
          </name>
          <name>
            <surname>Cui Zhou</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Gritsenko</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Blumenberg</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Karpova</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Petyuk</surname>
            <given-names>VA</given-names>
          </name>
          <name>
            <surname>Savage</surname>
            <given-names>SR</given-names>
          </name>
          <name>
            <surname>Satpathy</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Proteogenomic Characterization of Endometrial Carcinoma</article-title>
        <source>Cell</source>
        <year>2020</year>
        <volume>180</volume>
        <fpage>729</fpage>
        <lpage>748.e726</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cell.2020.01.026</pub-id>
        <?supplied-pmid 32059776?>
        <pub-id pub-id-type="pmid">32059776</pub-id>
      </element-citation>
    </ref>
    <ref id="CR8">
      <label>8.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Edwards</surname>
            <given-names>NJ</given-names>
          </name>
          <name>
            <surname>Oberti</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Thangudu</surname>
            <given-names>RR</given-names>
          </name>
          <name>
            <surname>Cai</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>McGarvey</surname>
            <given-names>PB</given-names>
          </name>
          <name>
            <surname>Jacob</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Madhavan</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Ketchum</surname>
            <given-names>KA</given-names>
          </name>
        </person-group>
        <article-title>The CPTAC Data Portal: A Resource for Cancer Proteomics Research</article-title>
        <source>J Proteome Res</source>
        <year>2015</year>
        <volume>14</volume>
        <fpage>2707</fpage>
        <lpage>2713</lpage>
        <pub-id pub-id-type="doi">10.1021/pr501254j</pub-id>
        <?supplied-pmid 25873244?>
        <pub-id pub-id-type="pmid">25873244</pub-id>
      </element-citation>
    </ref>
    <ref id="CR9">
      <label>9.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Gao</surname>
            <given-names>Q</given-names>
          </name>
          <name>
            <surname>Zhu</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Dong</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Shi</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Song</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Dong</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Zhou</surname>
            <given-names>Y</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma</article-title>
        <source>Cell</source>
        <year>2019</year>
        <volume>179</volume>
        <fpage>561</fpage>
        <lpage>577.e522</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cell.2019.08.052</pub-id>
        <?supplied-pmid 31585088?>
        <pub-id pub-id-type="pmid">31585088</pub-id>
      </element-citation>
    </ref>
    <ref id="CR10">
      <label>10.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hiam-Galvez</surname>
            <given-names>KJ</given-names>
          </name>
          <name>
            <surname>Allen</surname>
            <given-names>BM</given-names>
          </name>
          <name>
            <surname>Spitzer</surname>
            <given-names>MH</given-names>
          </name>
        </person-group>
        <article-title>Systemic immunity in cancer</article-title>
        <source>Nat Rev Cancer</source>
        <year>2021</year>
        <volume>21</volume>
        <fpage>345</fpage>
        <lpage>359</lpage>
        <pub-id pub-id-type="doi">10.1038/s41568-021-00347-z</pub-id>
        <?supplied-pmid 33837297?>
        <pub-id pub-id-type="pmid">33837297</pub-id>
      </element-citation>
    </ref>
    <ref id="CR11">
      <label>11.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Huang</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Chen</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Savage</surname>
            <given-names>SR</given-names>
          </name>
          <name>
            <surname>Eguez</surname>
            <given-names>RV</given-names>
          </name>
          <name>
            <surname>Dou</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>da Veiga Leprevost</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Jaehnig</surname>
            <given-names>EJ</given-names>
          </name>
          <name>
            <surname>Lei</surname>
            <given-names>JT</given-names>
          </name>
          <name>
            <surname>Wen</surname>
            <given-names>B</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma</article-title>
        <source>Cancer Cell</source>
        <year>2021</year>
        <volume>39</volume>
        <fpage>361</fpage>
        <lpage>379.e316</lpage>
        <pub-id pub-id-type="doi">10.1016/j.ccell.2020.12.007</pub-id>
        <?supplied-pmid 33417831?>
        <pub-id pub-id-type="pmid">33417831</pub-id>
      </element-citation>
    </ref>
    <ref id="CR12">
      <label>12.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>McDermott</surname>
            <given-names>JE</given-names>
          </name>
          <name>
            <surname>Arshad</surname>
            <given-names>OA</given-names>
          </name>
          <name>
            <surname>Petyuk</surname>
            <given-names>VA</given-names>
          </name>
          <name>
            <surname>Fu</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Gritsenko</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Clauss</surname>
            <given-names>TR</given-names>
          </name>
          <name>
            <surname>Moore</surname>
            <given-names>RJ</given-names>
          </name>
          <name>
            <surname>Schepmoes</surname>
            <given-names>AA</given-names>
          </name>
          <name>
            <surname>Zhao</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Monroe</surname>
            <given-names>ME</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Proteogenomic Characterization of Ovarian HGSC Implicates Mitotic Kinases, Replication Stress in Observed Chromosomal Instability</article-title>
        <source>Cell Rep Med</source>
        <year>2020</year>
        <volume>1</volume>
        <fpage>100004</fpage>
        <pub-id pub-id-type="doi">10.1016/j.xcrm.2020.100004</pub-id>
        <?supplied-pmid 32529193?>
        <pub-id pub-id-type="pmid">32529193</pub-id>
      </element-citation>
    </ref>
    <ref id="CR13">
      <label>13.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Pataskar</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Champagne</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Nagel</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Kenski</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Laos</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Michaux</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Pak</surname>
            <given-names>HS</given-names>
          </name>
          <name>
            <surname>Bleijerveld</surname>
            <given-names>OB</given-names>
          </name>
          <name>
            <surname>Mordente</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Navarro</surname>
            <given-names>JM</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Tryptophan depletion results in tryptophan-to-phenylalanine substitutants</article-title>
        <source>Nature</source>
        <year>2022</year>
        <volume>603</volume>
        <fpage>721</fpage>
        <lpage>727</lpage>
        <pub-id pub-id-type="doi">10.1038/s41586-022-04499-2</pub-id>
        <?supplied-pmid 35264796?>
        <pub-id pub-id-type="pmid">35264796</pub-id>
      </element-citation>
    </ref>
    <ref id="CR14">
      <label>14.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Satpathy</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Krug</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Jean Beltran</surname>
            <given-names>PM</given-names>
          </name>
          <name>
            <surname>Savage</surname>
            <given-names>SR</given-names>
          </name>
          <name>
            <surname>Petralia</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Kumar-Sinha</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Dou</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Reva</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Kane</surname>
            <given-names>MH</given-names>
          </name>
          <name>
            <surname>Avanessian</surname>
            <given-names>SC</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>A proteogenomic portrait of lung squamous cell carcinoma</article-title>
        <source>Cell</source>
        <year>2021</year>
        <volume>184</volume>
        <fpage>4348</fpage>
        <lpage>4371.e4340</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cell.2021.07.016</pub-id>
        <?supplied-pmid 34358469?>
        <pub-id pub-id-type="pmid">34358469</pub-id>
      </element-citation>
    </ref>
    <ref id="CR15">
      <label>15.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Schumacher</surname>
            <given-names>TN</given-names>
          </name>
          <name>
            <surname>Schreiber</surname>
            <given-names>RD</given-names>
          </name>
        </person-group>
        <article-title>Neoantigens in cancer immunotherapy</article-title>
        <source>Science</source>
        <year>2015</year>
        <volume>348</volume>
        <fpage>69</fpage>
        <lpage>74</lpage>
        <pub-id pub-id-type="doi">10.1126/science.aaa4971</pub-id>
        <?supplied-pmid 25838375?>
        <pub-id pub-id-type="pmid">25838375</pub-id>
      </element-citation>
    </ref>
    <ref id="CR16">
      <label>16.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tan</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Zhu</surname>
            <given-names>X</given-names>
          </name>
        </person-group>
        <article-title>Cancer immunotherapy: Pros, cons and beyond</article-title>
        <source>Biomed Pharmacother</source>
        <year>2020</year>
        <volume>124</volume>
        <fpage>109821</fpage>
        <pub-id pub-id-type="doi">10.1016/j.biopha.2020.109821</pub-id>
        <?supplied-pmid 31962285?>
        <pub-id pub-id-type="pmid">31962285</pub-id>
      </element-citation>
    </ref>
    <ref id="CR17">
      <label>17.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Tan</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Jian</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Wan</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Ouyang</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Lin</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Xie</surname>
            <given-names>L</given-names>
          </name>
        </person-group>
        <article-title>dbPepNeo: a manually curated database for human tumor neoantigen peptides</article-title>
        <source>Database (Oxford)</source>
        <year>2020</year>
        <volume>2020</volume>
        <fpage>baaa004</fpage>
        <pub-id pub-id-type="doi">10.1093/database/baaa004</pub-id>
        <?supplied-pmid 32090262?>
        <pub-id pub-id-type="pmid">32090262</pub-id>
      </element-citation>
    </ref>
    <ref id="CR18">
      <label>18.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Vigneron</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Stroobant</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Van den Eynde</surname>
            <given-names>BJ</given-names>
          </name>
          <name>
            <surname>van der Bruggen</surname>
            <given-names>P</given-names>
          </name>
        </person-group>
        <article-title>Database of T cell-defined human tumor antigens: the 2013 update</article-title>
        <source>Cancer Immun</source>
        <year>2013</year>
        <volume>13</volume>
        <fpage>15</fpage>
        <?supplied-pmid 23882160?>
        <pub-id pub-id-type="pmid">23882160</pub-id>
      </element-citation>
    </ref>
    <ref id="CR19">
      <label>19.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Waldman</surname>
            <given-names>AD</given-names>
          </name>
          <name>
            <surname>Fritz</surname>
            <given-names>JM</given-names>
          </name>
          <name>
            <surname>Lenardo</surname>
            <given-names>MJ</given-names>
          </name>
        </person-group>
        <article-title>A guide to cancer immunotherapy: from T cell basic science to clinical practice</article-title>
        <source>Nat Rev Immunol</source>
        <year>2020</year>
        <volume>20</volume>
        <fpage>651</fpage>
        <lpage>668</lpage>
        <pub-id pub-id-type="doi">10.1038/s41577-020-0306-5</pub-id>
        <?supplied-pmid 32433532?>
        <pub-id pub-id-type="pmid">32433532</pub-id>
      </element-citation>
    </ref>
    <ref id="CR20">
      <label>20.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>LB</given-names>
          </name>
          <name>
            <surname>Karpova</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Gritsenko</surname>
            <given-names>MA</given-names>
          </name>
          <name>
            <surname>Kyle</surname>
            <given-names>JE</given-names>
          </name>
          <name>
            <surname>Cao</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Rykunov</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Colaprico</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Rothstein</surname>
            <given-names>JH</given-names>
          </name>
          <name>
            <surname>Hong</surname>
            <given-names>R</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Proteogenomic and metabolomic characterization of human glioblastoma</article-title>
        <source>Cancer Cell</source>
        <year>2021</year>
        <volume>39</volume>
        <fpage>509</fpage>
        <lpage>528.e520</lpage>
        <pub-id pub-id-type="doi">10.1016/j.ccell.2021.01.006</pub-id>
        <?supplied-pmid 33577785?>
        <pub-id pub-id-type="pmid">33577785</pub-id>
      </element-citation>
    </ref>
    <ref id="CR21">
      <label>21</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yi</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Liao</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Wen</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Li</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Dou</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Savage</surname>
            <given-names>SR</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>B</given-names>
          </name>
        </person-group>
        <article-title>caAtlas: An immunopeptidome atlas of human cancer</article-title>
        <source>iScience</source>
        <year>2021</year>
        <volume>24</volume>
        <fpage>103107</fpage>
        <pub-id pub-id-type="doi">10.1016/j.isci.2021.103107</pub-id>
        <?supplied-pmid 34622160?>
        <pub-id pub-id-type="pmid">34622160</pub-id>
      </element-citation>
    </ref>
    <ref id="CR22">
      <label>22</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Chitkushev</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Olsen</surname>
            <given-names>LR</given-names>
          </name>
          <name>
            <surname>Keskin</surname>
            <given-names>DB</given-names>
          </name>
          <name>
            <surname>Brusic</surname>
            <given-names>V</given-names>
          </name>
        </person-group>
        <article-title>TANTIGEN 2.0: a knowledge base of tumor T cell antigens and epitopes</article-title>
        <source>BMC Bioinformatics</source>
        <year>2021</year>
        <volume>22</volume>
        <fpage>40</fpage>
        <pub-id pub-id-type="doi">10.1186/s12859-021-03962-7</pub-id>
        <?supplied-pmid 33849445?>
        <pub-id pub-id-type="pmid">33849445</pub-id>
      </element-citation>
    </ref>
    <ref id="CR23">
      <label>23.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Lu</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Qin</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Gao</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Tao</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Su</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Zhong</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>Neoantigen: A New Breakthrough in Tumor Immunotherapy</article-title>
        <source>Front Immunol</source>
        <year>2021</year>
        <volume>12</volume>
        <fpage>672356</fpage>
        <pub-id pub-id-type="doi">10.3389/fimmu.2021.672356</pub-id>
        <?supplied-pmid 33936118?>
        <pub-id pub-id-type="pmid">33936118</pub-id>
      </element-citation>
    </ref>
  </ref-list>
</back>
